Radical Prostatectomy News and Research

RSS

Radical prostatectomy is surgery to remove all of the prostate gland and some of the tissue around it, to treat prostate cancer.

High-risk prostate cancer patients benefit from perioperative apalutamide therapy

High-risk localized and locally advanced prostate cancer patients treated with apalutamide - a next generation neoadjuvant androgen-receptor pathway inhibitor (ARPI) - plus hormone therapy before and after prostate cancer surgery resulted in more major pathologic responses and reduced the risk of metastasis or death, meeting both primary endpoints, in an international phase 3 clinical trial led by principal investigator Mary-Ellen Taplin, MD, medical oncologist at Dana-Farber Cancer Institute, and Adam Kibel, MD, chair of the Department of Urology at Mass General Brigham.

31 May 2026

PSMA PET/CT scans may predict prostate cancer recurrence, guide treatment

New research in the February 2026 issue of JNCCN-Journal of the National Comprehensive Cancer Network found that incorporating information from prostate-specific membrane antigen (PSMA) PET/CT scans may be able to predict progression-free survival (PFS) and guide treatment planning in patients with rising prostate-specific antigen (PSA) levels following removal of the prostate.

9 Feb 2026

Novel laser focal therapy device shows promising results for prostate cancer treatment

Because treatment of the whole prostate can lead to long-term side effects in patients with prostate cancer, interest in minimally invasive, focal treatment options has been growing for certain patients.

28 Jan 2026

Single-port robotic surgery transforms cancer care at NYU Langone Hospital—Long Island

After enduring seven prior abdominal surgeries, 64-year-old Joy Monetti from Islip was no stranger to painful procedures and lengthy recoveries.

17 Nov 2025

Gene expression test identifies prostate cancer patients who benefit from hormone therapy

A new randomized study finds that a lab test that reads tumor genes can identify which patients with recurrent prostate cancer will benefit from adding hormone therapy to radiation after surgery - the first predictive biomarker in this setting.

29 Sep 2025

Frailty and microbial imbalance drive GI complications in bladder cancer surgery

Gastrointestinal (GI) complications, such as postoperative ileus (POI) and intra-abdominal infections (IAI), remain a major concern after radical cystectomy for bladder cancer.

8 Sep 2025

Androgen deprivation therapy lowers satisfaction after penile prosthesis surgery

Prostate cancer is the most common malignancy among men, with over 160,000 new cases diagnosed annually in the United States.

1 Sep 2025

New 'dual-mode' tracer agent enhances precision in prostate cancer procedures

A preclinical evaluation of a new 'dual-mode' tracer agent shows promise in not only helping surgeons image and plan prostate cancer procedures, but also provide them with much more consistent and targeted guidance during surgery.

21 Aug 2025

PSMA PET/CT improves outcomes for men with recurrent prostate cancer

A new study from Denmark shows for the first time that men with biochemically recurrent prostate cancer who undergo PSMA PET/CT before salvage radiotherapy have improved survival rates compared to those who do not.

14 Aug 2025

Rethinking prostate cancer risk in GG1 diagnoses

A new study reveals that some men who are diagnosed with "Grade Group one" (GG1) prostate cancer may actually be at higher risk than biopsy results suggest, according to research led by Weill Cornell Medicine, University Hospitals Cleveland and Case Western University.

31 Jul 2025

Shorter radiation treatment after surgery found safe for prostate cancer patients

For men who undergo a radical prostatectomy for the treatment of prostate cancer, post-surgery radiation therapy can play a vital role in reducing the risk of recurrence.

15 May 2025

Study reveals key genetic clues for prostate cancer progression

A recent study published in the Journal of Cancer Research and Clinical Oncology explored genetic predictors of prostate cancer progression to help identify its clinical outcomes.

18 Feb 2025

OncoAssure announces clinical validation of prostate cancer test

OncoAssure Ltd, an Irish medical diagnostic company, today announced the publication of new data, in the British Journal of Urology International Compass (BJUI Compass), which demonstrates the clinical validation of OncoAssure Prostate, a novel biopsy test which provides improved estimation of a patient’s risk of prostate cancer recurrence and allows for optimal treatment selection.

21 Jan 2025

AI-powered MRI predicts outcomes in prostate cancer

Researchers determine whether artificial intelligence-based MRI data could predict prostate cancer patient outcomes.

6 Nov 2024

High levels of microplastics found in prostate tumors, possibly linked to take-out food

Researchers discovered microplastics in both tumor and para-tumor prostate tissues, with higher concentrations found in tumor samples, raising concerns about their potential role in cancer development.

1 Oct 2024

Unfold AI outperforms conventional methods in prostate cancer risk prediction

A recently published study in BJUI Compass confirms the groundbreaking potential of Unfold AI™, an FDA-cleared artificial intelligence (AI) algorithm developed by Avenda Health, a leader in personalized prostate cancer care.

6 Sep 2024

Olaparib effective against BRCA2-mutated prostate cancer

The anti-cancer drug olaparib may be effective in treating biochemically recurrent prostate cancer without accompanying hormone therapy for men who have mutations in genes such as BRCA2, according to results of a phase II clinical trial of 51 patients conducted at the Johns Hopkins Kimmel Cancer Center and three other sites.

23 Aug 2024